Daily Bio News Summary — 2026-07-13

Today’s harvest landed 20 fresh news files across 7 distinct sources. The dominant theme is regulatory and deal flow: FDA posted new CRLs days after pausing the disclosure program, Boehringer’s nerandomilast (Jascayd) became Europe’s first new IPF drug in years, Q32 Bio’s anti-IL-7R antibody bempikibart jumped on Phase 2 alopecia data, and AstraZeneca’s new Sino Biopharm COPD pact surfaced via MedCity News. Endpoints News was fully soft-paywalled and contributed zero articles this run despite 13 candidates. STAT News and Reuters Biopharma contributed only filtered-out items (political, op-ed, author name, general market).

Today’s batch

FDA / regulatory

• FDA posts new rejection letters days after confirming pause (BioSpace, 2026-07-13) — The FDA last week confirmed that it would suspend the release of complete response letters pending the resolution of a citizen petition from an unnamed pharma c
• 5 FDA decisions to watch in the third quarter of 2026 (BioPharma Dive, 2026-07-13) — Tracker of the next quarter’s coming FDA decisions under the post-Makary leadership. The second quarter of 2026 marked a turning point for the Food
• HHS plan to speed drug research won’t remove ‘self-inflicted’ delays (BioPharma Dive, 2026-07-13) — The regulatory gears in the U.S. are increasingly creaking under the weight of new, complex drug technologies and intensifying overseas clinical trials competit

Pipelines / clinical readouts

• Q32 Bio stock jumps 60% on Phase 2 alopecia data (Fierce Biotech, 2026-07-13) — The latest phase 2 readout for Q32 Bio’s alopecia hopeful received a warm reception from investors, backing up the biotech’s claim that the drug could offer a more durable alternative to JAK inhibitors. The data, released Monday morning, come from part B of the Signal-AA study, which enrolled 33 patients with severe or very severe alopecia areata to receive the anti-IL-7R antibody bempikibart
• Agenus scraps ph. 3 colorectal study to narrow focus to colon (Fierce Biotech, 2026-07-13) — Agenus has scrapped a phase 3 study of its combo therapy in colorectal cancer after just three months in order to go all-in on colon cancer
• AB Science ends 3 studies in multiple sclerosis, other immune conditions (BioSpace, 2026-07-13) — The trials, which were testing the tyrosine kinase inhibitor masitinib, had previously been paused. AB Science’s decision not to resume them was a matter of pri
• GSK to seek FDA approval for Jemperli in high-profile cancer use (Fierce Pharma, 2026-07-13) — GSK says Jemperli has met the main goal of a Phase 2 trial in rectal cancer
• U.S. FDA Accepts BioMarin’s Supplemental NDA for full approval of Voxzogo for achondroplasia (PR Newswire FDA, 2026-07-13) — Application based on long-term safety and efficacy data from three ongoing studies

EU / UK pricing & access

• UK first in Europe to clear Boehringer’s IPF drug Jascayd (Pharmaphorum, 2026-07-13) — Boehringer Ingelheim has the first European approval for its new idiopathic pulmonary fibrosis (IPF) t
• NICE aims to cut funding for Amgen lung cancer drug Lumykras (Pharmaphorum, 2026-07-13) — Lumykras (Lumakras in some markets) will no longer be covered by the Cancer Drugs Fund
• NICE backs NHS use of non-invasive endometriosis tests (Pharmaphorum, 2026-07-13) — Women with endometriosis in England could soon be offered simple non-invasive tests for diagnosis of thei
• Germany approves controversial healthcare reform package (Fierce Pharma, 2026-07-13) — Even as the effort has met with fierce pushback from drugmakers, trade groups and opposition parties, German lawmakers late Frid

Deals / partnerships

• Insilico’s Chinese partner pens $177M pact for ‘mass market’ CNS target (Fierce Biotech, 2026-07-13) — China Medical System Holdings (CMS) has tapped existing partner Insilico Medicine for a CNS indication deal worth up to $177M
• AstraZeneca Turns to China for Molecule That Might Top New Merck COPD Drug (MedCity News, 2026-07-01) — AstraZeneca is getting rights to a Sino Biopharmaceutical drug that offers a dual mechanism to treat chronic obstructive pulmonary disease. Same approach as Merck’s FDA-approved drug

Public health / industry

• Island Pharma drug cleared for Bundibugyo Ebola use (Pharmaphorum, 2026-07-13) — Island Pharma has been granted the regulatory approvals needed to allow compassionate use of its antiviral g
• Top emerging biotech hubs in 2026 (Fierce Biotech, 2026-07-13) — Feature on biotech innovation centers outside Boston and South San Francisco
• Apnimed dreams of IPO to fund launch of sleep apnea pill (Fierce Biotech, 2026-07-12) — Apnimed is having sweet dreams of an IPO that could fund the planned commercial launch of an obstructive sleep apnea (OSA) therapy that is currently awaiting an FDA approval decision
• Biotechs forced to learn new patent tricks to protect pipelines (Fierce Biotech, 2026-07-12) — Feature on IP strategy as Chinese competition compresses trial timelines
• Biotech M&A is accelerating. Track the deals that are happening here. (BioPharma Dive, 2026-07-09) — Tracker article
• Obesity Is Tied to Hundreds of Gene Variants — Why Are We Only Talking About Two? (MedCity News, 2026-07-01) — Feature on obesity genetics and GLP-1 limitations

What this batch is NOT telling us

This is a moderate harvest day dominated by regulatory and clinical-readout items rather than M&A megadeals. Endpoints News was fully soft-paywalled — every one of its 13 candidates carried the “Sign up to read this article” / “BECOME A PREMIUM SUBSCRIBER” chrome despite being top-of-page headlines. That dropped what would normally be the day’s largest single-source contribution. STAT News and Reuters Biopharma each had multiple candidates but every one filtered out: STAT for political HHS/FDA commissioner candidates, first-person narratives, op-eds, an obituary, and an author-name sidebar leak; Reuters for general-market “Wall Street ends higher” copy and a Wainua Phase 3 fail that was already covered on 2026-07-10. The Fierce Pharma/Biotech articles all rendered cleanly via Camofox despite returning HTTP 403 to direct curl (Cloudflare bot protection, not paywall). China is the recurring cross-cutting theme: AstraZeneca’s COPD/Sino Biopharm pact, Insilico’s Chinese partner CMS deal, and Fierce Biotech’s patent-tricks feature all point to a sector adjusting to a faster, cheaper Chinese clinical-trial pipeline.

Reading order

If you have 90 seconds, read in this order:

1. Q32 Bio alopecia (Phase 2 readout + 60% stock jump — the day’s cleanest clinical story)
2. AstraZeneca + Sino Biopharm COPD (the molecule that may top Merck’s ensifentrine)
3. Boehringer Jascayd EU approval (first new IPF drug in years)
4. FDA posts new rejection letters (the latest wrinkle in the CRL transparency saga)
5. Agenus scraps ph. 3 CRC (pipeline-pruning signal — narrows to colon-only)

How to read the underlying articles

Each news file in src/content/news/ carries a sourceUrl field that links to the original article on the publisher’s site. Frontmatter pubDate, category, tags, and companyId are auto-generated. For company-specific stories, the matching profile is in src/content/companies/<companyId>.json (this run added 7 new company profiles: boehringer-ingelheim, amgen, biomarin-pharmaceutical, q32-bio, agenus, ab-science, apnimed).

---

All 20 items written today

1. FDA posts new rejection letters days after confirming pause — BioSpace — 2026-07-13
2. 5 FDA decisions to watch in the third quarter of 2026 — BioPharma Dive — 2026-07-13
3. HHS plan to speed drug research won’t remove ‘self-inflicted’ delays — BioPharma Dive — 2026-07-13
4. Q32’s stock jumps 60% on latest phase 2 alopecia data — Fierce Biotech — 2026-07-13 (companyId: q32-bio)
5. Agenus scraps ph. 3 colorectal study to narrow focus to colon — Fierce Biotech — 2026-07-13 (companyId: agenus)
6. Insilico’s partner pens $177M pact for ‘mass market’ CNS target — Fierce Biotech — 2026-07-13 (companyId: insilico-medicine)
7. AB Science ends 3 studies in multiple sclerosis, other immune conditions — BioSpace — 2026-07-13 (companyId: ab-science)
8. GSK to seek FDA approval for Jemperli in high-profile cancer use — Fierce Pharma — 2026-07-13
9. Germany approves controversial healthcare reform package — Fierce Pharma — 2026-07-13
10. Top emerging biotech hubs in 2026 — Fierce Biotech — 2026-07-13
11. Apnimed dreams of IPO to fund launch of sleep apnea pill — Fierce Biotech — 2026-07-12 (companyId: apnimed)
12. Biotechs forced to learn new patent tricks to protect pipelines — Fierce Biotech — 2026-07-12
13. UK first in Europe to clear Boehringer’s IPF drug Jascayd — Pharmaphorum — 2026-07-13 (companyId: boehringer-ingelheim)
14. NICE aims to cut funding for Amgen lung cancer drug Lumykras — Pharmaphorum — 2026-07-13 (companyId: amgen)
15. NICE backs NHS use of non-invasive endometriosis tests — Pharmaphorum — 2026-07-13
16. Island Pharma drug cleared for Bundibugyo Ebola use — Pharmaphorum — 2026-07-13
17. U.S. FDA Accepts BioMarin’s sNDA for full approval of Voxzogo — PR Newswire FDA — 2026-07-13 (companyId: biomarin-pharmaceutical)
18. AstraZeneca Turns to China for Molecule That Might Top New Merck COPD Drug — MedCity News — 2026-07-01
19. Obesity Is Tied to Hundreds of Gene Variants — Why Are We Only Talking About Two? — MedCity News — 2026-07-01
20. Biotech M&A is accelerating. Track the deals that are happening here. — BioPharma Dive — 2026-07-09